Physiomics PLC Approval of NIHR-funded PARTNER study (4635I)
14 Diciembre 2020 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 4635I
Physiomics PLC
14 December 2020
14 December 2020
Physiomics plc
("Physiomics" or "the Company")
Physiomics announces approval of NIHR-funded PARTNER study
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, is pleased to
announce that its National Institute for Health Research ("NIHR")
Invention for Innovation ("i4i") programme funded observational
clinical study (designated "PARTNER"), has this week received both
ethics committee and Health Research Authority (HRA) approval and
it is now expected that the study will commence early in 2021.
The PARTNER study is being funded by the UK Department of Health
& Social Care, which will provide 100% reimbursement of project
costs of up to GBP150,000 as announced on 10 March 2020. The award
project, "Further development of and evidence generation for a
precision dosing tool for optimising chemotherapy dosing in
advanced prostate cancer (NIHR201282)" will build on the Company's
successful work to date in developing a personalised oncology tool,
that has been funded mainly through Innovate UK grants in 2017 and
2018. In particular, the 2018 Innovate UK grant enabled the Company
to develop a demonstrator version of a decision support tool to
help clinicians treating late-stage prostate cancer to optimise the
dosing of docetaxel, a commonly used chemotherapy.
The PARTNER study, originally expected to run over a 12-month
period from April 2020, is, as a result of delays associated with
the ongoing COVID-19 epidemic, now expected to commence in early
2021. The delay does not impact the total cost or funding required
for the study. The study will generate data to further refine and
validate Physiomics' dosing tool and which could potentially be
used in future regulatory submissions.
Dr Jim Millen, CEO, said: " In parallel with this study,
Physiomics continues to seek additional opportunities to further
develop its personalised dosing tool and discussions are ongoing
with a company with an established presence in this field relating
to a trial of the tool. Further announcements will be made as
appropriate. "
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
About The National Institute for Health Research (NIHR)
The National Institute for Health Research (NIHR) is funded by
the Department of Health to improve the health and wealth of the
nation through research. The NIHR is the research arm of the NHS.
Since its establishment in April 2006, the NIHR has transformed
research in the NHS. It has increased the volume of applied health
research for the benefit of patients and the public, driven faster
translation of basic science discoveries into tangible benefits for
patients and the economy, and developed and supported the people
who conduct and contribute to applied health research. The NIHR
plays a key role in the Government's strategy for economic growth,
attracting investment by the life-sciences industries through its
world-class infrastructure for health research. Together, the NIHR
people, programmes, centres of excellence and systems represent the
most integrated health research system in the world. For further
information, visit the NIHR website ( www.nihr.ac.uk ).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFILFILFLII
(END) Dow Jones Newswires
December 14, 2020 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024